[Federal Register Volume 64, Number 18 (Thursday, January 28, 1999)]
[Notices]
[Page 4426]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-1937]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 98E-0475]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; Prandin (5,312,924)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined the 
regulatory review period for Prandin and is publishing this notice of 
that determination as required by law. FDA has made the determination 
because of the submission of an application to the Commissioner of 
Patents and Trademarks, Department of Commerce, for the extension of a 
patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the 
Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 
Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health 
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, 
Rockville, MD 20857, 301-827-6620.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term 
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug 
and Patent Term Restoration Act (Pub. L. 100-670) generally provide 
that a patent may be extended for a period of up to 5 years so long as 
the patented item (human drug product, animal drug product, medical 
device, food additive, or color additive) was subject to regulatory 
review by FDA before the item was marketed. Under these acts, a 
product's regulatory review period forms the basis for determining the 
amount of extension an applicant may receive.
     A regulatory review period consists of two periods of time: A 
testing phase and an approval phase. For human drug products, the 
testing phase begins when the exemption to permit the clinical 
investigations of the drug becomes effective and runs until the 
approval phase begins. The approval phase starts with the initial 
submission of an application to market the human drug product and 
continues until FDA grants permission to market the drug product. 
Although only a portion of a regulatory review period may count toward 
the actual amount of extension that the Commissioner of Patents and 
Trademarks may award (for example, half the testing phase must be 
subtracted as well as any time that may have occurred before the patent 
was issued), FDA's determination of the length of a regulatory review 
period for a human drug product will include all of the testing phase 
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
     FDA recently approved for marketing the human drug product Prandin 
(repaglinide). Prandin is indicated for use as an adjunct to diet and 
exercise to lower the blood glucose in patients with type 2 diabetes 
mellitus (non-insulin dependent diabetes mellitus) whose hyperglycemia 
cannot be controlled satisfactorily by diet and exercise alone. 
Subsequent to this approval, the Patent and Trademark Office received a 
patent term restoration application for Prandin (U.S. Patent No. 
5,312,924) from Dr. Karl Thomae GmbH, and the Patent and Trademark 
Office requested FDA's assistance in determining this patent's 
eligibility for patent term restoration. In a letter dated December 10, 
1998, FDA advised the Patent and Trademark Office that this human drug 
product had undergone a regulatory review period and that the approval 
of Prandin represented the first permitted commercial marketing or use 
of the product. Shortly thereafter, the Patent and Trademark Office 
requested that FDA determine the product's regulatory review period.
     FDA has determined that the applicable regulatory review period 
for Prandin is 2,091 days. Of this time, 1,916 days occurred during the 
testing phase of the regulatory review period, while 175 days occurred 
during the approval phase. These periods of time were derived from the 
following dates:
     1. The date an exemption under section 505 of the Federal Food, 
Drug, and Cosmetic Act (the act)(21 U.S.C. 355) became effective: April 
3, 1992. FDA has verified the applicant's claim that the date the 
investigational new drug application became effective was on April 3, 
1992.
     2. The date the application was initially submitted with respect 
to the human drug product under section 505 of the act: July 1, 1997. 
The applicant claims June 27, 1997, as the date the new drug 
application (NDA) for Prandin (NDA 20-741) was initially submitted.
     3. The date the application was approved: December 22, 1997. FDA 
has verified the applicant's claim that NDA 20-741 was approved on 
December 22, 1997.
     This determination of the regulatory review period establishes the 
maximum potential length of a patent extension. However, the U.S. 
Patent and Trademark Office applies several statutory limitations in 
its calculations of the actual period for patent extension. In its 
application for patent extension, this applicant seeks 747 days of 
patent term extension.
     Anyone with knowledge that any of the dates as published is 
incorrect may, on or before March 29, 1999, submit to the Dockets 
Management Branch (address above) written comments and ask for a 
redetermination. Furthermore, any interested person may petition FDA, 
on or before July 27, 1999, for a determination regarding whether the 
applicant for extension acted with due diligence during the regulatory 
review period. To meet its burden, the petition must contain sufficient 
facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th 
Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format 
specified in 21 CFR 10.30.
     Comments and petitions should be submitted to the Dockets 
Management Branch (address above) in three copies (except that 
individuals may submit single copies) and identified with the docket 
number found in brackets in the heading of this document. Comments and 
petitions may be seen in the Dockets Management Branch between 9 a.m. 
and 4 p.m., Monday through Friday.

    Dated: January 18, 1999.
Thomas J. McGinnis,
Deputy Associate Commissioner for Health Affairs.
[FR Doc. 99-1937 Filed 1-27-99; 8:45 am]
BILLING CODE 4160-01-F